<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>15</volume><submitter>Jurcik T</submitter><pubmed_abstract>The evidence for the use of Augmented Reality (AR) in treating specific phobias has been growing. However, issues of accessibility persist, especially in developing countries. The current study examined a novel, but relatively simple therapist guided smartphone-based AR Exposure Treatment (ARET) of spider phobia. Participants who reported symptoms of Arachnophobia were randomized into one of three comparison groups: ARET (&lt;i>n&lt;/i> = 20), traditional &lt;i>in vivo&lt;/i> exposure therapy (IVET; &lt;i>n&lt;/i> = 18) and a waitlist control group (&lt;i>n&lt;/i> = 17). Behavioral approach, subjective symptom measures, and galvanic skin response were assessed pre- and post-treatment. The study was concluded with a one-month follow up assessment. Results indicated that both treatment groups showed statistically significant and clinically meaningful improvements in behavioral approach at post-test that were maintained at 1 month follow- up, compared to the wait-listed group. Moreover, the treatment groups demonstrated significant improvements in subjective symptom report at 1-month follow up. Given its utility and potential accessibility, our findings suggest that future AR evaluation research could be conducted in therapy settings with minimal resources.</pubmed_abstract><journal>Frontiers in psychology</journal><pagination>1214125</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10911123</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>The efficacy of augmented reality exposure therapy in the treatment of spider phobia-a randomized controlled trial.</pubmed_title><pmcid>PMC10911123</pmcid><pubmed_authors>Adu P</pubmed_authors><pubmed_authors>Skuratov A</pubmed_authors><pubmed_authors>Samarina I</pubmed_authors><pubmed_authors>Kosonogov V</pubmed_authors><pubmed_authors>Demchenko A</pubmed_authors><pubmed_authors>Jurcik T</pubmed_authors><pubmed_authors>Krasavtseva Y</pubmed_authors><pubmed_authors>Mohammed AR</pubmed_authors><pubmed_authors>Sergeev N</pubmed_authors><pubmed_authors>Zaremba-Pike S</pubmed_authors><pubmed_authors>Kochetkov Y</pubmed_authors><pubmed_authors>Buranova N</pubmed_authors><pubmed_authors>Sawada T</pubmed_authors></additional><is_claimable>false</is_claimable><name>The efficacy of augmented reality exposure therapy in the treatment of spider phobia-a randomized controlled trial.</name><description>The evidence for the use of Augmented Reality (AR) in treating specific phobias has been growing. However, issues of accessibility persist, especially in developing countries. The current study examined a novel, but relatively simple therapist guided smartphone-based AR Exposure Treatment (ARET) of spider phobia. Participants who reported symptoms of Arachnophobia were randomized into one of three comparison groups: ARET (&lt;i>n&lt;/i> = 20), traditional &lt;i>in vivo&lt;/i> exposure therapy (IVET; &lt;i>n&lt;/i> = 18) and a waitlist control group (&lt;i>n&lt;/i> = 17). Behavioral approach, subjective symptom measures, and galvanic skin response were assessed pre- and post-treatment. The study was concluded with a one-month follow up assessment. Results indicated that both treatment groups showed statistically significant and clinically meaningful improvements in behavioral approach at post-test that were maintained at 1 month follow- up, compared to the wait-listed group. Moreover, the treatment groups demonstrated significant improvements in subjective symptom report at 1-month follow up. Given its utility and potential accessibility, our findings suggest that future AR evaluation research could be conducted in therapy settings with minimal resources.</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024</publication><modification>2026-06-16T04:52:52.751Z</modification><creation>2025-04-06T17:16:30.577Z</creation></dates><accession>S-EPMC10911123</accession><cross_references><pubmed>38440241</pubmed><doi>10.3389/fpsyg.2024.1214125</doi></cross_references></HashMap>